Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Heat Biologics Inc (HTBX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Today's Research Reports on Stocks to Watch: Axovant Sciences and Heat Biologics

NEW YORK, NY / ACCESSWIRE / June 7, 2018 / Axovant Sciences was one of the biggest gainers in the stock market on Wednesday after announcing that it has licensed an investigational gene therapy for Parkinson's...

HTBX : 2.21 (+5.24%)
AXON : 3.79 (+1.34%)
Heat Biologics to Present at the 2018 BIO International Convention

DURHAM, NC / ACCESSWIRE / May 30, 2018 / (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced its Chief Executive...

HTBX : 2.21 (+5.24%)
Complimentary Technical Snapshots on Heat Biologics and Three More Biotech Stocks

Stock Research Monitor: HEB, IBIO, and IDRA

HTBX : 2.21 (+5.24%)
IBIO : 1.22 (+4.27%)
Heat Biologics Reports First Quarter 2018 Results and Provides Corporate Update

(NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today reported financial and clinical updates for the first quarter ended March...

HTBX : 2.21 (+5.24%)
Heat Biologics, Inc. Announces Closing of $20.7 Million Public Offering

DURHAM, NC / ACCESSWIRE / May 7, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, today announced...

HTBX : 2.21 (+5.24%)
Biotechnology Companies Making Major Announcements

FN Media Group Presents Microcapspeculators.com News Commentary

PTCT : 37.55 (-2.19%)
HTBX : 2.21 (+5.24%)
NVCN : 0.03 (unch)
AKER : 0.41 (+5.13%)
ENDV : 0.0380 (+8.57%)
Today's Research Reports on Stocks to Watch: Heat Biologics and Immunomedics

NEW YORK, NY / ACCESSWIRE / May 1, 2018 / Both Heat Biologics and Immunomedics soared higher on Monday despite neither company having any news or catalyst to explain the jumps. Both stocks also saw tremendous...

HTBX : 2.21 (+5.24%)
Heat Biologics Announces Upcoming Milestones Following Positive Interim Phase 2 Results for HS-110

- Plans Interim Lung Cancer Phase 2 Readout in Q4 2018 and Final Readout in Q2 2019

HTBX : 2.21 (+5.24%)
Heat Biologics Reports Positive Data to Further Support the Mechanism of Action for its Proprietary T-Cell Activation Platform

100% of non-muscle invasive bladder cancer patients who generated an immune response to low dose HS-410 and also received standard of care BCG remain disease-free after 2 years

HTBX : 2.21 (+5.24%)
Heat Biologics and Its Pelican Therapeutics Subsidiary Appoint Anthony Tolcher, M.D., FRCPC, FACP to their Scientific Advisory Boards

DURHAM, NC / ACCESSWIRE / March 19, 2018 / Heat Biologics, Inc. (''Heat'') (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, along...

HTBX : 2.21 (+5.24%)
Heat Biologics Reports Fiscal Year 2017 Financial Results

/ Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, reported financial results for the fiscal year...

HTBX : 2.21 (+5.24%)
Heat Biologics Announces Positive Interim Data from its Phase 2 Clinical Trial of HS-110 and Nivolumab in Non-Small Cell Lung Cancer (NSCLC)

- Tumor Shrinkage and Disease Control Demonstrated in a Majority of Evaluable Patients

HTBX : 2.21 (+5.24%)
UPDATE: Heat Biologics to Host Analyst and Investor Event February 28, 2018, to Present Results from its Phase 2 Lung Cancer Study

Event to Be Webcast Live

HTBX : 2.21 (+5.24%)
BMY : 54.80 (+2.18%)
Heat Biologics Receives Recommendation from Independent Data Monitoring Committee to Continue Enrollment of Phase 2 Clinical Trial for HS-110 and Nivolumab for Treatment of Non-small Cell Lung Cancer

DURHAM, NC / ACCESSWIRE / February 20, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has...

HTBX : 2.21 (+5.24%)
Heat Biologics Announces Poster Presentation of Interim Phase 2 Lung Cancer Clinical Data for HS-110 and Nivolumab at the 2018 Keystone Symposia Conference XI: Immunological Memory: Innate, Adaptive and Beyond

DURHAM, NC / ACCESSWIRE / February 14, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, announces...

HTBX : 2.21 (+5.24%)
Technical Perspectives on Biotech Stocks -- Grifols, Heat Biologics, Hemispherx Biopharma, and iBio

WallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on GRFS, HTBX, HEB, and IBIO which can be accessed for free by signing up to www.wallstequities.com/registration....

HTBX : 2.21 (+5.24%)
GRFS : 23.14 (-2.45%)
Heat Biologics CEO, Jeff Wolf, to Present at the Upcoming BIO CEO & Investor Conference in New York

DURHAM, NC / ACCESSWIRE / February 7, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, will...

HTBX : 2.21 (+5.24%)
Today's Research Reports on Trending Tickers: Heat Biologics and ImmunoGen

NEW YORK, NY / ACCESSWIRE / February 1, 2018 / U.S. markets rallied late Wednesday to close in the green, with the Dow Jones and S&P 500 posting their best monthly gain since March 2016. The Dow Jones...

HTBX : 2.21 (+5.24%)
IMGN : 10.01 (-4.58%)
Heat Biologics to Host Analyst and Investor Event February 28, 2018 to Present Results from its Phase 2 Lung Cancer Study

Event will Highlight Clinical Data on First 35 Patients Dosed with HS-110 Plus Checkpoint Inhibitor Nivolumab (Opdivo®)

HTBX : 2.21 (+5.24%)
BMY : 54.80 (+2.18%)
Heat Biologics Announces Reverse Stock Split

DURHAM, NC / ACCESSWIRE / January 19, 2018 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a biopharmaceutical company developing drugs designed to activate a patient's immune system against cancer, has...

HTBX : 2.21 (+5.24%)

Van Meerten Stock Picks

5 Great Large Caps
This morning I wanted to find 5 Large Cap stocks that had performed well over the last year and still appeared to have some juice left in them.
ABMD +2.93 , NFLX -0.89 , VLO -1.64 , RL +0.62 , ALGN -3.61
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Agricharts Market Commentary

Today's Commentary

Corn futures closed with most nearby contracts 1 to 2 cents lower on Friday, despite showing gains at midday. Front month July lost 4.37% on the week. December fell to within 1 1/4 cents of the life of contract low in the overnight session. Managed m...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar